A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Eligible age
18–70 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency (AATD) via nebulization. This study is designed to evaluate safety and pharmacodynamics of KB408 in adults with AATD with a PI\*ZZ or PI\*ZNull genotype. Three planned dose levels of KB408 will be evaluated in single dose escalation cohorts. Repeat dosing will be evaluated at the mid dose level. Subjects taking intravenous AAT augmentation therapy are not required to wash out from IV AAT in the low and mid dose cohorts. In the repeat dose and the high dose cohorts, subjects must wash out from IV AAT for at least 10 days, as applicable.
Sponsor: Krystal Biotech, Inc.
You may qualify if…
- ✓ 1. The subject or legally authorized representative must have read, understood, and signed an Institutional Review Board (IRB) approved Informed Consent Form and must be willing and able to comply with study procedures and instructions.
- ✓ 2. Subject is aged ≥18 to ≤70 years, at the time of informed consent.
- ✓ 3. Subject has a genetically confirmed diagnosis of AATD with a PI\*ZZ or PI\*ZNull genotype.
- ✓ 4. Cohort 2b and Cohort 3: Subjects receiving AAT augmentation therapy must be willing to washout for at least 10 days prior to Screening and be willing to remain off augmentation therapy for the duration of the study.
- ✓ 5. Cohort 2b and Cohort 3: Serum AAT level \<11 μM at Screening.
- ✓ 6. Willing to remain on a stable regimen of treatment during the study.
- ✓ 7. Resting oxygen saturation ≥92% on room air at Screening.
- ✓ 8. Clinically stable and in good general health, except for AATD, as determined by the Investigator.
You may not qualify if…
- ✕ 1. Pulmonary function test with percent predicted forced expired volume in 1 second (ppFEV1) after inhalation of a bronchodilator is \<40% at Screening.
- ✕ 2. Diffusing capacity of the lungs for carbon monoxide (DLCO) \<30 percent predicted (historical DLCO within 2 years prior to Screening without any intervening change in clinical status since the measurement was taken, or as measured at Screening).
- ✕ 3. Known ongoing or history of clinically significant pulmonary impairment other than AATD.
- ✕ 4. A pulmonary exacerbation within six weeks (42 days) of first dose.
- ✕ 5. Initiation of any new chronic therapy or any change in ongoing therapy routine within 28 days of first dose.
- ✕ 6. Participation in another interventional clinical study or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, of first dose. Previous treatment with a genetic therapy for AATD, where the investigational product was demonstrated to be non-efficacious, is not exclusionary.
- ✕ 7. History of or listed for solid organ transplantation or has undergone major lung surgery (e.g., lobectomy) within 6 months of first dose.
- ✕ 8. Any clinical condition or illness (including a history or current evidence of substance abuse or dependence) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB408.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06049082 · last updated 2025-07-22